Andreas Huth

This inventor holds 66 USPTO granted patents and 5 published patent applications and 1 EPO patent, primarily in VEGF Inhibitors (CPC class 5142). Top assignees: Schering Aktiengesellschaft, Bayer Schering Pharma Ag, Novartis Ag. Active years: 1979-2011.

USPTO Granted Patents = 66 (Patent Applications = 5)

% Patents Active = 71.2

EPO Patents = 1

Average Co-Inventor Count = 5.9

ph-index = 12

Forward Citations = 506(Granted Patents)

Forward Citations (Not Self Cited) = 378(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

55 out of 1,409

Schering Aktiengesellschaft

patents

6 out of 192

Bayer Schering Pharma Ag

Scnering Aktiengesellschaft

7. 1 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1979-2011

Loading Chart...

Areas of Expertise:

VEGF Receptor Kinase

Tumor Diagnosis

Pharmaceutical Derivatives

Anthranilamide

Benzamide Derivatives

Carboline Derivatives

Heterocycles

Nicotinamide

Pyridinureas

Inhibitory Compounds

Medicaments

Oxazolidinone

66 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7906533 - Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors (2011-03-15),

2. 7902229 - Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors (2011-03-08),

3. 7850948 - Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy (2010-12-14),

4. 7615565 - VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines (2009-11-10),

5. 7572794 - Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors (2009-08-11),

6. 7517894 - VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines (2009-04-14),

7. 7479491 - Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors (2009-01-20),

8. 7459470 - N-oxide anthranylamide derivatives and their use as medicaments (2008-12-02),

9. 7429592 - Cyanoanthranilamide derivatives and the use thereof as medicaments (2008-09-30),

10. 7427390 - Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy (2008-09-23),

11. 7202260 - VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones (2007-04-10),

12. 7148357 - VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines (2006-12-12),

13. 7122547 - Anthranilic acid amides and the use thereof as medicaments (2006-10-17),

14. 7081468 - Ortho-substituted anthranilic acid amides and their use as medicaments (2006-07-25),

15. 7012081 - Anthranyl amides and their use as medicaments (2006-03-14),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I would be pleased to assist you with the article about inventor Andreas Huth.

Title: Unveiling the Innovative Mind of Andreas Huth

Introduction:

Andreas Huth is a prolific inventor based in Berlin, Germany, with a remarkable intellect that has led to the creation of numerous groundbreaking patents in the field of pharmaceuticals and biotechnology.

Latest Patents:

1. "Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors."

2. "Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors."

Career Highlights:

With an impressive portfolio of 66 patents, Andreas Huth has proven his expertise in developing novel pharmaceutical agents aimed at preventing and treating diseases triggered by persistent angiogenesis. His patents showcase a deep understanding of VEGF receptor kinase inhibitors and their role in combating ailments associated with abnormal blood vessel growth.

Collaborations:

Throughout his career, Andreas Huth has collaborated with esteemed professionals in the industry, including Dieter Seidelmann and Ralph Schmiechen. His collaborations have fueled innovative ideas and facilitated the development of cutting-edge solutions to complex medical challenges.

Conclusion:

Andreas Huth's dedication to advancing medical science through his inventive spirit is truly commendable. His contributions to the field of pharmaceuticals have not only transformed the landscape of healthcare but also inspired future generations of inventors to push the boundaries of innovation further.

If you seek more information on Andreas Huth or any other innovative minds, feel free to explore our platform idiyas.com for a plethora of inspiring stories and discoveries in the world of patents and inventions.